[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355392-105":59,"doc-detail-355392-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-machine-learning-assay-to-predict-disease-recurrence-in-hormone-receptor-positive-breast-cancer","A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer","","Hormone receptor-positive, HER2-negative breast cancer carries a long-term risk of relapse, and existing multigene assays have limited ability to distinguish clinically low-risk tumors from those with high recurrence risk. This study develops ER-Predict, a machine learning assay based on a 14-gene expression signature, trained on 1413 early-stage cases and externally validated across eight public cohorts (1118 samples). ER-Predict shows independent prognostic value beyond clinicopathological factors, outperforms recomputed panels, and suggests cell-cycle inhibitor actionability for high-risk tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-machine-learning-assay-to-predict-disease-recurrence-in-hormone-receptor-positive-breast-cancer/355392/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-machine-learning-assay-to-predict-disease-recurrence-in-hormone-receptor-positive-breast-cancer/355392.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What disease and patient subgroup does the study target?","Question",{"text":112,"@type":113},"The study focuses on hormone receptor-positive, HER2-negative early-stage breast cancer patients, emphasizing relapse risk over time.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is ER-Predict constructed and validated?",{"text":117,"@type":113},"ER-Predict is built using a 14-gene expression signature trained on 1413 cases and externally validated across eight publicly available cohorts totaling 1118 samples.",{"name":119,"@type":110,"acceptedAnswer":120},"Does ER-Predict add value beyond traditional clinical factors?",{"text":121,"@type":113},"Yes. ER-Predict demonstrates independent prognostic value beyond factors such as tumor grade, tumor size, and nodal status, and it consistently outperforms recomputed multigene panels.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355392,1790295432,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","ORIGINAL ARTICLE  \nA machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer  \nL. Boscolo Bielo1 , 2 , 3 ∗, D. Trapani1 , 2, P. Razavi3 ,4, S. Chandarlapaty3 , 4 , 5, Y. Zhan2 , 6 ∗ & G. Curigliano1 , 2 ∗  \n1Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan; 2Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; 3Breast Medicine Service, Department of Medicine, MSK, New York; 4Weill-Cornell Medical College, New York; 5Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA; 6Diagnostica Molecolare Avanzata, Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy  \nAvailable online 2 March 2026  \nBackground: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer associates with a sustained risk of relapse over time. Current multigene assays offer limited validity to identify clinically low-risk tumors at high risk of recurrence, which is particularly relevant in the context of novel adjuvant therapies. In this study, we developed and validated ER-Predict, a machine learning assay leveraging a 14-gene expression signature to classify early stage HR-positive/HER2-negative breast cancer according to the risk of relapse. Materials and methods: ER-Predict was developed on a cohort of 1413 HR-positive/HER2-negative early breast cancer cases. External validation was carried out across eight publicly available cohorts (n = 1118) . Comparative benchmarking was conducted against reproduced prognostic signatures, and particularly, EndoPredict and Oncotype DX. Functional annotation and drug response analysis were carried out using gene expression and pharmacogenomic data from publicly available breast cancer cell lines.  \nResults: ER-Predict identified high-risk patients with significantly reduced distant metastasis-free survival in the external validation cohort (hazard ratio 2.03, 95% confidence interval 1.57-2.63, P \u003C 0.0001) . The assay demonstrated independent prognostic value beyond traditional clinicopathological factors, including tumor grade, tumor size, and nodal status, and consistently outperformed recomputed multigene panels. ER-Predict showed specificity toward luminal-like transcriptomic programs, revealing activation of key cell-cycle regulators governing endocrine resistance among high-risk tumors that had retained expression of retinoblastoma-1, suggesting potential actionability by means of cell-cycle inhibitors.  \nConclusions: ER-Predict represents a robust assay with potential utility in early stage HR-positive/HER2-negative breast cancer. Its consistent ability to identify high-risk patients supports further investigation as a decision-support tool to guide treatment intensification in clinically low-risk HR-positive/HER2-negative disease.  \nKey words: machine learning, artificial intelligence, breast cancer, recurrence prediction  \n*Correspondence to: Dr Luca Boscolo Bielo, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, via G. Ripamonti 435, 20141, Milan, Italy; Breast Medicine Service, Department of Medicine, MSK, New York, NY 10065, USA. Tel: +1-646-234-6585  \nE-mails: [luca.boscolobielo@ieo.it](luca.boscolobielo@ieo.it) [or](or boscoll@mskcc.org)[ boscoll@mskcc.org](or boscoll@mskcc.org) (L. Boscolo Bielo).  \nDr Yinxiu Zhan, Diagnostica Moleculare Avanzata, Department of Experimental Oncology, European Institute of Oncology, Via Adamello, 16, 20139 Milan, MI, Italy. Tel: +39-3341959139  \nE-mail: [yinxiu.zhan@ieo.it](yinxiu.zhan@ieo.it) (Y. Zhan).  \nProf. Giuseppe Curigliano, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, via G. Ripamonti 435, 20141 Milan, Italy. Tel: +39-3389081408  \nE-mail: [giuseppe.curigliano@ieo.it](giuseppe.curigliano@ieo.it) (G. Curigliano).  \n @curijoey  \n2059-7029/© 2026 T","cbCaiffSfMOwyDQA","https://ap.wps.com/l/cbCaiffSfMOwyDQA","pdf",10192320,14,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Key words","[{\"question\":\"What disease and patient subgroup does the study target?\",\"answer\":\"The study focuses on hormone receptor-positive, HER2-negative early-stage breast cancer patients, emphasizing relapse risk over time.\"},{\"question\":\"How is ER-Predict constructed and validated?\",\"answer\":\"ER-Predict is built using a 14-gene expression signature trained on 1413 cases and externally validated across eight publicly available cohorts totaling 1118 samples.\"},{\"question\":\"Does ER-Predict add value beyond traditional clinical factors?\",\"answer\":\"Yes. ER-Predict demonstrates independent prognostic value beyond factors such as tumor grade, tumor size, and nodal status, and it consistently outperforms recomputed multigene panels.\"}]","A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer | PDF",1790118439,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6bd2eb3eb44abead0134d85d11c48b1.webp",983,1269,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d1f80d4a626b1a697f0e0696af7ce95.webp",982,1268,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0645780babee711c06f377c9f8b06f31.webp",981,1266,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00f1132c035ac6e4f149cdcb72728ec6.webp",980,1265]